Dynamic monitoring of carcinoembryonic antigen, CA19-9 and inflammation-based indices in patients with advanced colorectal cancer undergoing chemotherapy

Table 6 Diagnostic characteristics of carcinoembryonic antigen, carbohydrate antigen, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and systemic immune-inflammation index

Parameters	Se	Sp	PPV	NPV	CUI-(Ve+)	CUI-(Ve-)	FC
CEA	86.9 (78.4-95.4)	79.7 (73.1-86.3)	64.6 (54.3-75.0)	93.4 (89.1-97.8)	0.561 (0.44-0.68)	0.752 (0.64-0.80)	81.94
CA19-9	80.6 (67.6-95.5)	72.5 (62.7-82.3)	56.9 (43.3-70.5)	89.2 (81.7-96.8)	0.46 (0.29-0.63)	0.652 (0.57-0.73)	753
NLR	68.8 (53.2-84.0)	66.7 (56.4-76.9)	47.1 (33.4-60.8)	83.1 (74.0-92.2)	0.32 (0.14-0.50)	0.551 (0.46-0.64)	67.2
PLR	53.8 (34.7-73.1)	81.3 (67.7-94.8)	70.0 (49.9-90.1)	68.4 (53.6-83-2)	0.38 (0.13-0.62)	0.551 (0.43-0.68)	69
CII	70.3 (55.5-85.0)	65.9 (55.6-76.1)	48.1 (34.8-61.5)	83.1 (74.0-97.2)	0.34 (0.16-0.50)	0.551 (0.46-0.64)	67.2

¹Satisfactory/adequate clinical utility index (CUI).

²Good CUI.

³Overall utility satisfactory/adequate.

⁴Overall utility good. A qualitative interpretation of the clinical utility index: (E) ≥ 0.81 excellent; (G) ≥ 0.64 good; (SA) ≥ 0.49 satisfactory/adequate; (P) ≥ 0.36 poor; (VP) < 0.36 very poor. Se: Sensitivity; Sp: Specificity; PPV: Positive predictive value; NPV: Negative predictive value; CUI+: Clinical utility index positive; CUI-: Clinical utility index negative; FC: Fraction correct; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; SII: Systemic immune-inflammation index.